TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19632665
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg oral misoprostol (group 2)
Study: 19632665
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional medication (group 3)
Study: 17020910
Drug: High-dose diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose diazepam (15 mg)
Study: 17020910
Drug: Low-dose diazepam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose diazepam (5 mg)
Study: 9394987
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of gold sodium thiomalate
Study: 3368545
Drug: Low-dose neuroleptics
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose neuroleptics
Study: 3368545
Drug: Low-dose neuroleptics
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose neuroleptics (excluding relapsed patients)
Study: 20631375
Drug: Romiplostim 750
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim 750 μg
Study: 21519749
Drug: Flaxseed powder
Normalized name: Flaxseed Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed powder (60 g/day, 10 g ALA)
Study: 21519749
Drug: Isocaloric roasted
Normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric roasted cassava powder (60 g/day, fat-free)
Study: 7691775
Drug: Grid laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grid laser treatment (low energy scatter photocoagulation applied to areas of presumed CNV and abnormal retinal pigment epithelium, sparing the fovea)
Study: 7691775
Drug: Grid laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grid laser treatment and Natural course (control group)
Study: 27941937
Drug: Pegylated-interferon-alpha-2b monotherapy
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegylated-interferon-alpha-2b monotherapy or combination therapy with adefovir dipivoxil
Study: 24323035
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/d continuously plus prednisone 5 mg twice daily
Study: 12860491
Drug: Simvastatin (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40-80 mg)
Study: 12860491
Drug: Atorvastatin (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20-80 mg)
Study: 8905602
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol
Study: 7506866
Drug: Cefotiam 4
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotiam 4 g a day for 7 days (arm A)
Study: 7506866
Drug: Tosufloxacin 300
Normalized name: tosufloxacin
DrugBank: Tosufloxacin (DB16850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tosufloxacin 300 mg a day for 7 days (arm B)
Study: 19824561
Drug: G-Bond
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond
Study: 20463100
Drug: Calcium load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium load (600 mg of calcium carbonate)
Study: 12816288
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration (GTR) with anti-infective therapy (metronidazole gel, chlorhexidine gluconate 0.2%, doxycycline 100 mg x 1/day for 6 to 8 weeks, ibuprofen 3 x 400 mg/day for 7 days)
Study: 12816288
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration (GTR) without anti-infective therapy (chlorhexidine gluconate 0.2% for 1 week, doxycycline 100 mg x 1/day for 1 week, ibuprofen 3 x 400 mg/day for 7 days)
Study: 10519578
Drug: Intracameral 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral 1% unpreserved lidocaine combined with topical anesthesia (oxybuprocaine)
Study: 10519578
Drug: Peribulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar anesthesia with 6 ml prilocaine
Study: 2477130
Drug: Cibenzoline (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (130 to 160 mg bid)
Study: 2477130
Drug: Cibenzoline (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (130 to 160 mg bid) in phase 2
Study: 30571546
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17β‐estradiol per day
Study: 30571546
Drug: 2+2 mg
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2+2 mg 17β‐estradiol per day
Study: 21709093
Drug: Finafloxacin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finafloxacin (up to 800 mg)
Study: 21709093
Drug: Finafloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finafloxacin (400 mg and above)
Study: 15329112
Drug: sustained-release alfuzosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release alfuzosin 5 mg twice daily
Study: 9333329
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 10% (200/0.5) at 12 ml per kg body-weight daily
Study: 28058714
Drug: Myo‐inositol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo‐inositol 1000 mg, Tribulus Terrestris 300 mg, Alga Ecklonia Bicyclis 200 mg and Biovis one tablet a day for 90 days
Study: 28058714
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet a day for 90 days
Study: 24490577
Drug: Jiangzhikangyanghua mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangzhikangyanghua mixture 20 mL tid + amlodipine 5 mg qd + valsartan 80 mg qd
Study: 24490577
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg qd + valsartan 80 mg qd
Study: 21328025
Drug: G-CSF (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (1.5 μg/kg) injected for 14 consecutive days
Study: 10999555
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 300 mg/d
Study: 30656993
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g every 6 hours)
Study: 25251999
Drug: Lipegfilgrastim 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipegfilgrastim 25 µg/kg (body-weight-adjusted)
Study: 25251999
Drug: Lipegfilgrastim 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipegfilgrastim 50 or 100 μg/kg
Study: 25251999
Drug: Lipegfilgrastim 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipegfilgrastim 6 mg (fixed-dose)
Study: 25251999
Drug: Pegfilgrastim 100
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim 100 μg/kg
Study: 25251999
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg (fixed-dose)
Study: 21675542
Drug: Emotion-focused self-regulation
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion-focused self-regulation strategies (e.g., comfort seeking)
Study: 21675542
Drug: Planful self-regulation
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Planful self-regulation strategies (e.g., distraction)
Study: 19532850
Drug: Tramadol/acetaminophen and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/acetaminophen and naloxone infusion (0.25 microg/kg/h for 48 hours)
Study: 19532850
Drug: Tramadol/acetaminophen and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/acetaminophen and naloxone infusion
Study: 19532850
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (historical controls)
Study: 16765847
Drug: Sesame oil
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame oil (SO) 5 ml by mouth at bedtime
Study: 16765847
Drug: Placebo 5
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 ml by mouth at bedtime
Study: 15325416
Drug: Caffeine 3
Normalized name: caffeine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3 mg/kg body weight
Study: 15325416
Drug: Caffeine 5
Normalized name: caffeine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 5 mg/kg body weight
Study: 9257377
Drug: Topical retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical retinol preparation
Study: 9257377
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E cream
Study: 8382234
Drug: Amlodipine (231
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (231 patients, 5-10 mg/day)
Study: 8382234
Drug: Enalapril (230
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (230 patients, 10-40 mg/day)
Study: 3791659
Drug: Ethanol ingestion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol ingestion (1.5 ml/kg initial dose, maintained at 110-140 mg%)
Study: 31898656
Drug: Interdigitated HDRICBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdigitated HDRICBT with EBRT 50 Gy/25 fractions and 8 Gy/fraction weekly for three fractions
Study: 31898656
Drug: Sequential HDRICBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential HDRICBT with EBRT 50 Gy/25 fractions and 8 Gy/fraction weekly for three fractions
Study: 23136031
Drug: Lowered dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowered dialysate sodium concentration from 140 mmol/l to 138 mmol/l
Study: 21640057
Drug: Traditional visual/tactile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional visual/tactile oral examination
Study: 19996424
Drug: Chlorproguanil-dapsone-artesunate (CDA)
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chlorproguanil-dapsone-artesunate (CDA) 2.0/2.5/4.0 mg/kg, once daily for 3 days
Study: 19996424
Drug: Chlorproguanil-dapsone (CPG-DDS)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorproguanil-dapsone (CPG-DDS) 2.0/2.5 mg/kg, once daily for 3 days
Study: 11333852
Drug: Home-based dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based dietary treatment with locally available foods and micronutrient supplements
Study: 9005975
Drug: Hexarelin (HEX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexarelin (HEX) combined with pyridostigmine (PD) 120 mg orally
Study: 8504051
Drug: 15 micrograms/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 micrograms/g calcitriol ointment applied twice daily
Study: 29479099
Drug: Routine periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine periodontal treatment methods for streptococcal gingivitis
Study: 29479099
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment with antacid chewing tablet two times a day for a week
Study: 16352688
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg daily for 2 months
Study: 9058444
Drug: Modified Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Group (MG, n = 22)
Study: 8436149
Drug: Bisoprolol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 2.5 mg per day
Study: 8436149
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg per day
Study: 2936370
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (10 mg)
Study: 2936370
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (0.6 mg)
Study: 2936370
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebulized salbutamol and ipratropium bromide
Study: 28008244
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110 μg/50 μg
Study: 28008244
Drug: Salmeterol/fluticasone (SFC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone (SFC) 50 μg/500 μg
Study: 24916694
Drug: Low-dose Fulvestrant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Fulvestrant
Study: 20397858
Drug: Hold-Relax-Antagonist Contraction
Normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hold-Relax-Antagonist Contraction (HR-AC) stretching technique
Study: 18498909
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with olmesartan medoxomil (OM) and amlodipine besylate (AML)
Study: 18498909
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with OM and AML
Study: 18498909
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) monotherapy
Study: 18498909
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate (AML) monotherapy
Study: 18498909
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with OM/AML 20/10 mg and 40/10 mg
Study: 12526069
Drug: Erythromycin 50
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 50 mg/kg/day for 14 days
Study: 12526069
Drug: Amoxicillin 75
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 75 mg/kg/day for 7 days
Study: 10536434
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% topical solution for 1 week
Study: 10536434
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% topical solution for 4 weeks
Study: 10536434
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% solution (subgroup without protocol violation)
Study: 10536434
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% solution (subgroup without protocol violation)
Study: 8871416
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy plus the nicotine patch (BTP)
Study: 8871416
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy alone (BT)
Study: 1649867
Drug: Oral potassium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral potassium supplements
Study: 6366132
Drug: Simultaneous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous therapy (MTX 200 mg/m2 IV and 5-FU 600 mg/m2 IV)
Study: 6366132
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (MTX 200 mg/m2 IV followed by 5-FU 600 mg/m2 IV after one hour)
Study: 6366132
Drug: Simultaneous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous therapy (MTX 200 mg/m2 IV and 5-FU 600 mg/m2 IV) among stage III patients
Study: 6366132
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (MTX 200 mg/m2 IV followed by 5-FU 600 mg/m2 IV after one hour) among stage III patients
Study: 31529590
Drug: JNJ-9375 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-9375 (0.3 to 1.8 mg/kg)
Study: 29768313
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg orally)
Study: 29768313
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg orally)
Study: 26950829
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg twice daily (BID)
Study: 26950829
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg once daily (QD)
Study: 21702254
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg midazolam as pre‐medication 1 hour preoperatively
Study: 21702254
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as pre‐medication
Study: 17339813
Drug: Medication intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication intervention, frequency 3 to 5 times per week, duration 45 to 60 minutes, total period 12 to 24 weeks.
Study: 16382062
Drug: Repeated thrombolysis
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated thrombolysis vs Conservative therapy
Study: 16382062
Drug: Rescue PCI
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue PCI vs Conservative therapy
Study: 9856539
Drug: Drinking milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking milk (300 ml)
Study: 9856539
Drug: Drinking water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking water (300 ml)
Study: 7796718
Drug: Current users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current users of anabolic steroids
Study: 7796718
Drug: Former users
Normalized name: Triple Wormer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Former users of anabolic steroids
Study: 7796718
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of anabolic steroids
Study: 2131953
Drug: Alginate-antacid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate-antacid (1 tablet to be chewed 30 min after each meal and at bed time)
Study: 2131953
Drug: Famotidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (1 mg/kg before supper at 7 pm)
Study: 374847
Drug: Commercial aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial aqueous pilocarpin solution
Study: 30614850
Drug: Hyoscine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine 0.3 mg
Study: 27557443
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment (8-11 sessions of Electromyography biofeedback, Vasoconstriction-/Vasodilatation training, or a combination)
Study: 22224655
Drug: Curcumin (L-D+)
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (L-D+)
Study: 22224655
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (L+D+)
Study: 17706718
Drug: Detrusor injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detrusor injection of 100 U botulinum toxin type A
Study: 17706718
Drug: Suburothelial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suburothelial injection of 100 U botulinum toxin type A
Study: 17706718
Drug: Bladder base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder base injection of 100 U botulinum toxin type A
Study: 2724028
Drug: 0.05% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% NaF solution (control)
Study: 29124991
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance treatment
Study: 27114587
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate during interim maintenance 1
Study: 27114587
Drug: Dexamethasone and
Normalized name: dexamethasone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone and high-dose methotrexate
Study: 23535292
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bid BDP + RTV for 28 days
Study: 23535292
Drug: 600/100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/100 mg bid BDP + DRV/r for 28 days
Study: 19853533
Drug: EBRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT with rV(100%) >= 0.05 cc
Study: 19853533
Drug: EBRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT with rV(100%) < 0.05 cc
Study: 19853533
Drug: EBRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT with dose to hottest 0.1 cc
Study: 19853533
Drug: EBRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT with dose to hottest 1%
Study: 19853533
Drug: EBRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT with dose to hottest 3%
Study: 18212693
Drug: Group corticosteroid
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group corticosteroid (Group S) received 6-methylprednisolone 15 mg/kg IV 60 min before induction.
Study: 18212693
Drug: Group TEA+corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group TEA+corticosteroid (Group TEA+S) received 20 mg bupivacaine in bolus 60 min before induction followed by 20 mg/h bupivacaine infusion intraoperatively and postoperatively via epidural catheter.
Study: 18212693
Drug: Group TEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group TEA (Group TEA) received 20 mg bupivacaine in bolus 60 min before induction followed by 20 mg/h bupivacaine infusion intraoperatively and postoperatively via epidural catheter.
Study: 18212693
Drug: Group control
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group control (Group C) received neither preinduction TEA nor a preinduction steroid.
Study: 9128319
Drug: MISO TID
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MISO TID (200 microg three times daily)